Skip to main content

Table 7 Cost-effectiveness (95% CI) of ART compared to no-ART under different scenarios

From: Cost-effectiveness of anti-retroviral therapy at a district hospital in southern Ethiopia

Strategy Life time Cost $ Life time incremental cost Life years gain Incremental life years gain Cost effectiveness ($) Incremental Cost Effectiveness ratio (ICER $) % change from base case ICER
a)        
no-ART 264(82–1046)   2.4(1.99–2.82)   110(36–433)   
ART 2713(1038–5883) 2448(653–5665) 10.4(9.45–11.23) 8(6.96–8.91) 262(101–564) 307(83–708) -2.2
b)        
no-ART 265(85–1148)   2.3(1.95–2.73)   114(38–504)   
ART 3022(1486–6054) 2757(1080–5885) 11.4(10.46–12.41) 9.1(8.03–10.18) 264(129–525) 303(121–634) -3.5
c)        
no-ART 265(85–1148)   2.3(1.95–2.73)   114(38–504)   
ART* 2537(1281–4859) 2273(851–4647) 9.4(8.67–10.05) 7.1(6.24–7.83) 271(137–519) 322(120–662) 2.6
ART** 2576(1313–4937) 2311(844–4740) 9.4(8.67–10.05) 7.1(6.24–7.83) 275(141–525_ 328(123–668) 4.5
ART*** 2672(1413–5069) 2407(1020–4841) 9.4(8.67–10.05) 7.1(6.24–7.83) 285(151–539) 341(145–684) 8.6
d)        
no-ART 265(85–1148)   2.3(1.95–2.73)   114(38–504)   
ART 1150(621–2099) 886(-100–1924) 4.3(3.99–4.67) 2.0(1.49–2.53) 266(145–482) 441(-49–1009) 40.5
  1. a) if all patients initially start from the non-AIDS state
  2. b) if the model runs until all the patents in the ART cohort die
  3. c) if different amounts of one time additional costs are included for patients dying under the ART scenario
  4. d) if effect of ART is limited to cycles that correspond to the observation period and has no effect thereafter.
  5. (i.e. Treatment effect only for the first 11 cycles)
  6. * if additional cost for dying patients = $70
  7. ** if additional cost for dying patients = $117
  8. *** if additional cost for dying patients = $233